HK1068501A1 - Pdgf-bb for the treatment of parkinson's disease - Google Patents

Pdgf-bb for the treatment of parkinson's disease

Info

Publication number
HK1068501A1
HK1068501A1 HK05101145.7A HK05101145A HK1068501A1 HK 1068501 A1 HK1068501 A1 HK 1068501A1 HK 05101145 A HK05101145 A HK 05101145A HK 1068501 A1 HK1068501 A1 HK 1068501A1
Authority
HK
Hong Kong
Prior art keywords
pdgf
treatment
methods
disorder
nervous system
Prior art date
Application number
HK05101145.7A
Other languages
English (en)
Inventor
Kioumars Delfani
Ann Marie Janson
Georg H Kuhn
Karlheinz Plate
Anne Schanzer
Frank-Peter Wachs
Ming Zhao
Original Assignee
Neuronova Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26983933&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1068501(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuronova Ab filed Critical Neuronova Ab
Publication of HK1068501A1 publication Critical patent/HK1068501A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/49—Platelet-derived growth factor [PDGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/515—Angiogenesic factors; Angiogenin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
HK05101145.7A 2001-09-19 2005-02-12 Pdgf-bb for the treatment of parkinson's disease HK1068501A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32338101P 2001-09-19 2001-09-19
US32604401P 2001-09-28 2001-09-28
PCT/IB2002/003998 WO2003024478A1 (en) 2001-09-19 2002-09-19 Treatment of central nervous system disorders by use of pdgf or vegf

Publications (1)

Publication Number Publication Date
HK1068501A1 true HK1068501A1 (en) 2005-04-22

Family

ID=26983933

Family Applications (2)

Application Number Title Priority Date Filing Date
HK11106377.7A HK1152243A1 (en) 2001-09-19 2005-02-12 Vegf for use in the treatment of central nervous system disorders vegf
HK05101145.7A HK1068501A1 (en) 2001-09-19 2005-02-12 Pdgf-bb for the treatment of parkinson's disease

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK11106377.7A HK1152243A1 (en) 2001-09-19 2005-02-12 Vegf for use in the treatment of central nervous system disorders vegf

Country Status (10)

Country Link
US (2) US7981863B2 (de)
EP (3) EP2266594B1 (de)
AU (1) AU2002334327B2 (de)
CA (1) CA2461176C (de)
CY (1) CY1113699T1 (de)
DK (2) DK2266594T3 (de)
ES (2) ES2396545T3 (de)
HK (2) HK1152243A1 (de)
PT (2) PT1443955E (de)
WO (1) WO2003024478A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9694038B2 (en) * 2000-04-06 2017-07-04 Wayne P. Franco Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
CA2444632A1 (en) * 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
CA2444624A1 (en) * 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7943376B2 (en) * 2001-04-27 2011-05-17 Stem Cell Therapuetics Inc. Platelet derived growth factor (PDGF)-derived neurospheres define a novel class of progenitor cells
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
AU2003213078A1 (en) * 2002-02-14 2003-09-04 Buck Institute Neurogenerative or neurotrophic factors for mitigating a symptom of ischemia
GB0205772D0 (en) * 2002-03-12 2002-04-24 Gill Steven S Catheter
US20040014662A1 (en) * 2002-05-08 2004-01-22 Per Lindquist Modulation of neural stem cells and neural progenitor cells
US7998460B2 (en) * 2003-04-17 2011-08-16 The Board Of Trustees Of The Leland Stanford Junior University Prevention of deficits in neurogenesis with anti-inflammatory agents
EP1622577A4 (de) * 2003-04-17 2007-09-26 Univ Leland Stanford Junior Prävention von neurogenese-defiziten mit entzündungshemmenden mitteln
EP1663188B1 (de) * 2003-09-12 2016-08-10 Newron Sweden AB Behandlunge von erkrankungen des nervensystems
EP1663293A2 (de) * 2003-09-23 2006-06-07 Ludwig Institute For Cancer Research Vege-cor vege-d-materialien und verfahren zur stimulation der neuralen stammzellen
US20070269412A1 (en) * 2003-12-02 2007-11-22 Celavie Biosciences, Llc Pluripotent cells
US20080118480A1 (en) * 2003-12-19 2008-05-22 Imclone Systems Incorporated Methods and Compositions for Directing Migration of Neural Progenitor Cells
EP2365077B1 (de) * 2004-03-12 2013-05-08 Alnylam Pharmaceuticals, Inc. iRNA-Agenten zum VEGF-Targeting
ATE478678T1 (de) * 2004-05-27 2010-09-15 Vib Vzw Behandlung von amyotrohper lateralsklerose
WO2006055743A2 (en) * 2004-11-18 2006-05-26 Franco, Wayne Compbination growth therapy and cell therapy for treatment of acute and chronic diseases of the organs
US20080025962A1 (en) * 2004-11-30 2008-01-31 Angesmg,Inc. Remedy for Alzheimer's Disease
CA2589343A1 (en) * 2004-12-01 2006-06-08 Stem Cell Therapeutics Corporation Platelet-derived growth factor-responsive neural precursor cells and progeny thereof
SG170780A1 (en) * 2006-03-31 2011-05-30 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of eg5 gene
WO2007124308A2 (en) * 2006-04-17 2007-11-01 Ludwig Institute For Cancer Research Methods and compositions for modulation of blood-neural barrier
US8598333B2 (en) * 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
US20080044847A1 (en) 2006-06-23 2008-02-21 Shusta Eric V Blood-Brain Barrier Model
CN100445373C (zh) * 2006-12-04 2008-12-24 山东大学 黄樟素氧化物在内皮细胞与神经干细胞培养体系中的应用
DE102007019162A1 (de) * 2007-04-20 2008-10-23 Johann Wolfgang Goethe-Universität Frankfurt am Main Verwendung von EGFL7 zur Modulation von Zellen
EA201301171A1 (ru) * 2008-03-05 2014-10-30 Элнилэм Фармасьютикалз, Инк. Композиции и способы ингибирования экспрессии генов eg5 и vegf
ES2376930B1 (es) * 2009-02-05 2013-01-24 Universidad Del Pais Vasco Método para el tratamiento de enfermedades neurodegenerativas.
US20100209399A1 (en) * 2009-02-13 2010-08-19 Celavie Biosciences, Llc Brain-derived stem cells for repair of musculoskeletal system in vertebrate subjects
WO2010137547A1 (ja) 2009-05-25 2010-12-02 国立大学法人東京工業大学 中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物
AU2012249491B2 (en) 2011-04-29 2016-12-15 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
ES2657078T3 (es) * 2011-06-01 2018-03-01 Universität Heidelberg Agente activador de VEGFR2/3 para uso en el tratamiento de disfunciones cognitivas
US9415090B2 (en) 2011-06-01 2016-08-16 Universität Heidelberg VEGF-D/VEGFR2/3-mediated regulation of dendrites
EP2529745A1 (de) * 2011-06-01 2012-12-05 Universität Heidelberg VEGF-D/VEGFR-vermittelte Regulierung von Dendriten
WO2014004990A2 (en) 2012-06-29 2014-01-03 Celgene Corporation Methods for determining drug efficacy using cereblon-associated proteins
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
RU2542385C2 (ru) * 2012-08-31 2015-02-20 Общество с ограниченной ответственностью "НекстГен" Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека
EP3079692A4 (de) * 2013-12-09 2017-10-18 Thomas Jefferson University Neuartiges verfahren zur behandlung einer neurodegenerativen krankheit bei einem säugetier mit derartigem bedarf
US10369329B2 (en) 2014-01-30 2019-08-06 Renishaw Plc Neurosurgical apparatus and method
US10272117B2 (en) 2014-02-24 2019-04-30 Celgene Corporation Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
US10144778B2 (en) * 2014-03-12 2018-12-04 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
JP6640126B2 (ja) 2014-06-27 2020-02-05 セルジーン コーポレイション セレブロン及び他のｅ３ユビキチンリガーゼの立体構造の変化を誘導するための組成物及び方法
WO2016092453A1 (en) * 2014-12-07 2016-06-16 Ramot At Tel-Aviv University Ltd. Prevention or reversal of apoe4 induced brain pathology by activation of vegf receptors
GB201506052D0 (en) 2015-04-09 2015-05-27 Renishaw Plc Movement disorder
RU2612497C2 (ru) 2015-05-26 2017-03-09 Общество с ограниченной ответственностью "НекстГен" Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf
WO2017117118A1 (en) 2015-12-28 2017-07-06 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
US11007228B2 (en) * 2016-02-05 2021-05-18 Kyungpook National University Industry-Academic Cooperation Foundation Pharmaceutical composition containing stem cell in which vascular endothelial growth factor is overexpressed as effective ingredient for preventing or treating neurodegenerative disease
RU2639175C1 (ru) * 2016-11-14 2017-12-20 Общество с ограниченной ответственностью "НекстГен" Способ индукции регенерации периферического нерва
US20230033523A1 (en) * 2021-07-30 2023-02-02 The Research Foundation For The State University Of New York Method of treating cerebral autosomal dominant arteriopathy with subcortical infarct and leukoencephalopathy (cadasil)

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692147A (en) 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5219759A (en) * 1987-04-22 1993-06-15 Chiron Corporation Recombinant DNA encoding PDGF A-chain polypeptide and expression vectors
US4899919A (en) 1988-04-01 1990-02-13 Clumb Thomas E Self energizing fastener system
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
IT1237435B (it) * 1989-12-14 1993-06-04 Farmaco attivo nel ripristino della plasticita' neuronale.
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6071889A (en) * 1991-07-08 2000-06-06 Neurospheres Holdings Ltd. In vivo genetic modification of growth factor-responsive neural precursor cells
US6497872B1 (en) * 1991-07-08 2002-12-24 Neurospheres Holdings Ltd. Neural transplantation using proliferated multipotent neural stem cells and their progeny
US5980885A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. Growth factor-induced proliferation of neural precursor cells in vivo
US6294346B1 (en) * 1991-07-08 2001-09-25 Neurospheres Holdings, Ltd. Use of multipotent neural stem cells and their progeny for the screening of drugs and other biological agents
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU673659B2 (en) 1991-11-25 1996-11-21 Institute Of Molecular Biology, Inc. Medicament for promoting growth of mammalian nerve
CA2140638C (en) 1992-07-24 2010-05-04 Raju Kucherlapati Generation of xenogeneic antibodies
AU7568094A (en) * 1993-08-12 1995-03-14 Cytotherapeutics, Inc. Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2214439C (en) * 1995-03-02 2002-12-17 Amrad Operations Pty. Ltd. A novel growth factor and a genetic sequence encoding same
US5670477A (en) 1995-04-20 1997-09-23 Joseph F. Poduslo Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (de) 1995-04-28 2001-09-19 Abgenix Inc Menschliche antikörper aus xenomäusen
US5711316A (en) 1996-04-30 1998-01-27 Medtronic, Inc. Method of treating movement disorders by brain infusion
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6042579A (en) 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
US6165783A (en) * 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
EP1060242A4 (de) 1998-01-23 2003-09-17 Imclone Systems Inc Aufbereitete stammzell-populationen
ES2389387T3 (es) 1998-03-17 2012-10-25 Genentech, Inc. Polipéptidos homólogos de VEGF y de BMP1
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
DK1112083T3 (da) * 1998-09-09 2004-03-08 Univ Washington Behandling af mikrovaskulære angiopatier
US6432673B1 (en) * 1998-12-07 2002-08-13 Zymogenetics, Inc. Growth factor homolog ZVEGF3
WO2000075163A1 (en) * 1999-06-03 2000-12-14 Human Genome Sciences, Inc. Angiogenic proteins and uses thereof
JP2003507349A (ja) 1999-08-18 2003-02-25 ザ ゼネラル ホスピタル コーポレーション 中枢神経系への損傷からの回復を促進する方法、組成物およびキット
ATE468863T1 (de) 1999-09-21 2010-06-15 Anges Mg Inc Gentherapie für zerebrale gefässerkrankungen
WO2001049849A1 (en) 2000-01-05 2001-07-12 Zymogenetics, Inc. Novel fgf homolog zfgf11
US7582292B2 (en) * 2000-02-26 2009-09-01 Artecel, Inc. Adipose tissue derived stromal cells for the treatment of neurological disorders
CA2404616C (en) 2000-04-12 2009-08-18 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of vegf and homologues to treat neuron disorders
US7943376B2 (en) 2001-04-27 2011-05-17 Stem Cell Therapuetics Inc. Platelet derived growth factor (PDGF)-derived neurospheres define a novel class of progenitor cells
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
WO2005016963A2 (en) * 2003-06-12 2005-02-24 Ludwig Institute For Cancer Research Heparin binding veger-3 ligands
EP2548578B1 (de) * 2006-05-17 2014-08-20 The Ludwig Institute for Cancer Research Targeting der Regulierung von Fettsäuretransportern durch VEGF-B zur Modulation menschlicher Krankheiten
US20100135970A1 (en) * 2006-10-27 2010-06-03 Caritas St. Elizabeth Medical Center Of Boston, In Methods for Reprogramming Adult Somatic Cells and Uses Thereof

Also Published As

Publication number Publication date
US7981863B2 (en) 2011-07-19
AU2002334327B2 (en) 2006-05-04
WO2003024478A1 (en) 2003-03-27
US20030203844A1 (en) 2003-10-30
DK2266594T3 (en) 2015-08-10
CA2461176A1 (en) 2003-03-27
EP1443955A1 (de) 2004-08-11
HK1152243A1 (en) 2012-02-24
EP1443955B1 (de) 2012-09-12
ES2546093T3 (es) 2015-09-18
EP2289537A1 (de) 2011-03-02
PT2266594E (pt) 2015-08-05
PT1443955E (pt) 2012-12-26
EP2266594A1 (de) 2010-12-29
ES2396545T3 (es) 2013-02-22
EP2266594B1 (de) 2015-05-27
CA2461176C (en) 2013-11-05
CY1113699T1 (el) 2016-06-22
WO2003024478A9 (en) 2003-06-05
US20120077741A1 (en) 2012-03-29
DK1443955T3 (da) 2013-01-02

Similar Documents

Publication Publication Date Title
HK1068501A1 (en) Pdgf-bb for the treatment of parkinson's disease
WO2003039575A3 (en) Use of reelin, gas6, and protein s in the treatment of neural disorders
WO2003094965A8 (en) Modulation of neural stem cells with s1p or lpa receptor agonists
WO2003092716A3 (en) Therapeutic use of pacap, maxadilan, pacap receptor agonist and/or adcyap1r1 in the treatment of cns disorders
EP1361229A3 (de) Verwendung von Tyrosine Kinase (PYK2) zur Produktion von Antikörper
HK1011972A1 (en) 3-(3,4-Dioxyphenyl)-pyrrolidines as type iv phosphodiesterase inhibitors for the treatment of inflammatory diseases
ATE212375T1 (de) Modifizierter ciliary neurotrophic factor (cntf), und verfahren zu dessen herstellung und verwendung
MX9706969A (es) 3-(1,2,3,6-tetrahidropiridin-4-il)-1h-indoles y 3-(piperidin-4-il)-1h-indoles sustituidos en la posicion 5: agonistas del 5-ht1f novedosos.
NO962130D0 (no) Synergistisk behandling av Parkinsons sykdom
BRPI0410296A (pt) sistema e método para a determinação da eficácia de tratamento de distúrbios neurológicos utilizando o eletroencefalograma
HK1104836A1 (en) Recombinant alpha-l-iduronidase and methods for treating diseases caused by deficiencies thereof
EP2324834A3 (de) Verfahren zur Steigerung des endogenen Erythropoietins
ATE229806T1 (de) Wirkstoff zur behandlung neurodegenerativer störungen
DE59810761D1 (de) Verwendung von vasopressin-antagonisten zur behandlung von störungen oder erkrankungen des innenohres
PL345275A1 (en) Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders
BRPI0214821B8 (pt) método para determinar a responsividade de indivíduo com distúrbio psicótico ao tratamento com loperidona
HK1018272A1 (en) Substituted pyridylmethylpiperazine and piperidinederivatives, their preparation and their use for treating central nervous system (cns) disorders
WO2002079235A3 (en) Compositions and methods for modulating guanylyl cyclase signaling receptor (gc-c) activity and for treating meniere's disease
HK1049153A1 (en) Adenosine receptor antagonists and methods of making and using the same
EP1632248B8 (de) Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen
DE69635213D1 (de) Verwendung von Olanzapin zur Behandlung von mentalen Erkrankungen verursacht durch zerebrovaskuläre Erkrankungen
EP1254260A4 (de) Methoden zur diagnose und behandlung von herzkrankheiten
ATE113591T1 (de) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol- - one und ihre verwendung als antikonvulsiva.
ATE123942T1 (de) 5-aryl-3h-1,2,4-triazol-3-one und ihre verwendung als antikonvulsiva.
TR199802200A2 (xx) S�lfonamid s�bstit�e edilmi� benzopiran t�revleri, �retilme y�ntemi.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170919